Pfizer to invest over €1.2bn in Belgian manufacturing facility
US-based pharmaceutical company Pfizer has unveiled its plans to invest more than €1.2bn in its manufacturing facility in Puurs, Belgium, over a period of three years. Last week,
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XUS-based pharmaceutical company Pfizer has unveiled its plans to invest more than €1.2bn in its manufacturing facility in Puurs, Belgium, over a period of three years. Last week,
Rigel Pharmaceuticals has secured the US Food and Drug Administration (FDA) approval for Rezlidhia (olutasidenib) to treat a type of acute myeloid leukaemia (AML) in adults. The drug
German biotechnology company BioNTech has entered into a €40m multi-target research collaboration with Polish biopharmaceutical company Ryvu Therapeutics. Under the collaboration, the two companies will jointly develop several
British drugmaker AstraZeneca has signed an agreement to acquire Neogene Therapeutics, a Dutch clinical-stage biotechnology company, for a total consideration of up to $320m. The transaction consideration includes
UK-based drug discovery company C4X Discovery has signed a $402m exclusive global licensing agreement with pharmaceutical company AstraZeneca, for its NRF2 Activator programme. Under the terms of the
Chinese biopharmaceutical company Everest Medicines said that regulatory authorities in Taiwan and South Korea have granted fast-tracked approval process for Nefecon. Nefecon is a patented oral, delayed release
Scientists at the University of Pennsylvania, Perelman School of Medicine have created a flu vaccine that offers protection against all 20 known influenza A and B virus subtypes.
AbbVie has received the European Commission (EC) approval for Skyrizi (risankizumab) to treat moderate to severe Crohn’s disease in adults. Skyrizi is a humanised monoclonal antibody inhibitor that
CSL Behring has received the US Food and Drug Administration (FDA) approval for Hemgenix (etranacogene dezaparvovec-drlb) to treat adults with haemophilia B. Hemgenix is a gene therapy that
Merck, also known as MSD outside the US and Canada, has entered into a definitive agreement to acquire US-based biopharmaceutical company Imago BioSciences for a total equity value